Altre lingue Olema Pharmaceuticals, Inc.

Azioni

OLMA

US68062P1066

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
9,83 ^USD	-3,15%		-0,71%	-29,94%

02/04	OLEMA PHARMACEUTICALS, INC. : il giudizio da Goldman Sachs è ora al rialzo	ZM
12/03	OLEMA PHARMACEUTICALS, INC. : HC Wainwright ribadisce il giudizio positivo sul titolo	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference	08/04
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index	18/03
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update	11/03
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors	06/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors	06/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors	06/03
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03
Olema Oncology to Participate in Upcoming Investor Conferences	06/02
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08/01
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08/01
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference	02/01
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to NASDAQ Biotechnology Index	18/12
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies	05/12
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies	05/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Olema Pharmaceuticals, Inc.

Azioni

OLMA

US68062P1066

Altre lingue

Filtri